



Vibativ® (telavancin) – Product Discontinuation

- The [FDA announced](#) the discontinuation of [Vibativ \(telavancin\)](#) 250 mg vials due to business reasons.
 - The discontinuation is not due to product quality, safety or efficacy concerns.
 - Per Theravance Biopharma, the majority of Vibativ use is with the 750 mg vial.
 - The Vibativ 750 mg/vial injection is still available.
- Vibativ is indicated for the treatment of adult patients with complicated skin and skin structure infections caused by susceptible isolates of certain Gram-positive microorganisms, and for the treatment of adult patients with hospital-acquired and ventilator-associated bacterial pneumonia, caused by susceptible isolates of *Staphylococcus aureus* (both methicillin-susceptible and -resistant isolates).
- Other currently available antibiotics within the same lipoglycopeptide class include [Dalvance® \(dalbavancin\)](#) and [Orbactiv® \(oritavancin\)](#). Refer to their respective drug labels for specific indication information.



OptumRx® specializes in the delivery, clinical management and affordability of prescription medications and consumer health products. We are an Optum® company — a leading provider of integrated health services. Learn more at [optum.com](#).

All Optum® trademarks and logos are owned by Optum, Inc. All other brand or product names are trademarks or registered marks of their respective owners.

This document contains information that is considered proprietary to OptumRx and should not be reproduced without the express written consent of OptumRx.

Rx News® is published by the OptumRx Clinical Services Department.

©2016 Optum, Inc. All rights reserved.